11 facts about venlafaxine Review article
Article Sidebar
Published:
Jun 20, 2022
Keywords:
depressive disorders, anxiety disorders, SSRIs, pain, duloxetine, comorbidity, serotonin syndrome
Main Article Content
Abstract
Venlafaxine is one of the selective serotonin and noradrenaline reuptake inhibitors, but it has nearly 30 times stronger affinity for the serotonin transporter. In practice, this means evolution of the drug mechanism, potency and therapeutic profile with the dose. The paper presents the practical possibilities of using this feature of venlafaxine in various clinical situations.
Article Details
How to Cite
Siwek , M. (2022). 11 facts about venlafaxine. Medycyna Faktow (J EBM), 15(2(55), 174-180. https://doi.org/10.24292/01.MF.0222.9
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Siwek M. Dekalog leczenia depresji – wydanie 2021. Item Publishing, Warszawa 2021.
2. Gorostowicz A, Siwek M. Wenlafaksyna – właściwości farmakologiczne oraz zastosowanie w praktyce klinicznej. Medycyna Faktów. 2018; 11(3): 199-205.
3. Furukawa TA, Cipriani A, Cowen PJ et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019; 6(7): 601-9. http://doi.org/10.1016/S2215-0366(19)30217-2.
4. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66.
5. Bauer M, Tharmanathan P, Volz HP et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009; 259(3): 172-85.
6. Tundo A, de Filippis R, Proietti L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J Psychiatry. 2015; 5(3): 330-41.
7. Li X, Zhu L, Su Y et al. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: a meta-analysis. PLoS One. 2017; 12(10): e0185865.
8. Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013; 28(1): 33-45.
9. Gosmann NP, Costa MA, Jaeger MB et al. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. PLoS Med. 2021; 18(6): e1003664. http://doi.org/10.1371/journal.pmed.1003664.
10. Siwek M, Krupa A. Leki przeciwdepresyjne w terapii bólu. In: Dudek D, Siwek M, Woroń J (ed). Ból i depresja. Termedia, Poznań 2021.
11. Aiyer R, Barkin RL, Bhatia A. Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review. Pain Med. 2016: 1-14. http://doi.org/10.1093/pm/pnw261.
12. Durand JP, Deplanque G, Montheil V et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012; 23: 200-5.
13. Vanderweide LA, Smith MPH, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. J Clin Pharm Ther. 2015; 40: 1-6. http://doi.org/10.1111/jcpt.12216.
14. Siwek M. Pacjent z depresją i bólem – diagnostyka i leczenie. In: Dobrogowski J, Wordliczek J, Woroń J (ed). Leczenie bólu w praktyce lekarza POZ. Termedia, Poznań 2019.
15. Begré S, Traber M, Gerber M et al. Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: An observational study in primary care. Eur Psychiatry. 2008; 23: 178-86. http://doi.org/10.1016/j.eurpsy.2008.01.001.
16. Huang X, Li Ch, Luo Y et al. Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms. NeuroReport. 2013; 24(7): 364-9. http://doi.org/10.1097/WNR.0b013e3283601a3e.
17. Woroń J, Siwek M, Gorostowicz A. Niepożądane efekty interakcji leków psychotropowych z produktami leczniczymi stosowanymi w chorobach układu sercowo-naczyniowego. Psychiatr Pol. 2019; 53(5): 977-95.
18. Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017; 102(1): 37-44. http://doi.org/10.1002/cpt.597.
19. Bazire S. Psychotropic Drug Directory 2020/21. RLP, UK 2020.
20. Charakterystyka produktu leczniczego: wenlafaksyna.
21. Warner CH, Bobo W, Warner C et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006; 74(3): 449-56.
2. Gorostowicz A, Siwek M. Wenlafaksyna – właściwości farmakologiczne oraz zastosowanie w praktyce klinicznej. Medycyna Faktów. 2018; 11(3): 199-205.
3. Furukawa TA, Cipriani A, Cowen PJ et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019; 6(7): 601-9. http://doi.org/10.1016/S2215-0366(19)30217-2.
4. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66.
5. Bauer M, Tharmanathan P, Volz HP et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009; 259(3): 172-85.
6. Tundo A, de Filippis R, Proietti L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J Psychiatry. 2015; 5(3): 330-41.
7. Li X, Zhu L, Su Y et al. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: a meta-analysis. PLoS One. 2017; 12(10): e0185865.
8. Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013; 28(1): 33-45.
9. Gosmann NP, Costa MA, Jaeger MB et al. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. PLoS Med. 2021; 18(6): e1003664. http://doi.org/10.1371/journal.pmed.1003664.
10. Siwek M, Krupa A. Leki przeciwdepresyjne w terapii bólu. In: Dudek D, Siwek M, Woroń J (ed). Ból i depresja. Termedia, Poznań 2021.
11. Aiyer R, Barkin RL, Bhatia A. Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review. Pain Med. 2016: 1-14. http://doi.org/10.1093/pm/pnw261.
12. Durand JP, Deplanque G, Montheil V et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012; 23: 200-5.
13. Vanderweide LA, Smith MPH, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. J Clin Pharm Ther. 2015; 40: 1-6. http://doi.org/10.1111/jcpt.12216.
14. Siwek M. Pacjent z depresją i bólem – diagnostyka i leczenie. In: Dobrogowski J, Wordliczek J, Woroń J (ed). Leczenie bólu w praktyce lekarza POZ. Termedia, Poznań 2019.
15. Begré S, Traber M, Gerber M et al. Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: An observational study in primary care. Eur Psychiatry. 2008; 23: 178-86. http://doi.org/10.1016/j.eurpsy.2008.01.001.
16. Huang X, Li Ch, Luo Y et al. Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms. NeuroReport. 2013; 24(7): 364-9. http://doi.org/10.1097/WNR.0b013e3283601a3e.
17. Woroń J, Siwek M, Gorostowicz A. Niepożądane efekty interakcji leków psychotropowych z produktami leczniczymi stosowanymi w chorobach układu sercowo-naczyniowego. Psychiatr Pol. 2019; 53(5): 977-95.
18. Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017; 102(1): 37-44. http://doi.org/10.1002/cpt.597.
19. Bazire S. Psychotropic Drug Directory 2020/21. RLP, UK 2020.
20. Charakterystyka produktu leczniczego: wenlafaksyna.
21. Warner CH, Bobo W, Warner C et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006; 74(3): 449-56.